Alliancebernstein L.P. Inhibrx, Inc. Transaction History

Alliancebernstein L.P.

$275 Billion
Q1 2024

A detailed history of Alliancebernstein L.P. transactions in Inhibrx, Inc. stock. As of the latest transaction made, Alliancebernstein L.P. holds 35,860 shares of INBX stock, worth $508,136. This represents 0.0% of its overall portfolio holdings.

Number of Shares

35,860

Previous 71,489 49.84%

Holding current value

$508,136

Previous $2.72 Million 53.87%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$32.76 - $39.56 $1.17 Million - $1.41 Million	-35,629 Reduced 49.84%	35,860 $1.25 Million
Q4 2023 Feb 14, 2024	SELL	$14.5 - $38.0 $290,580 - $761,520	-20,040 Reduced 21.89%	71,489 $2.72 Million
Q3 2023 Nov 14, 2023	BUY	$15.75 - $26.31 $725,949 - $1.21 Million	46,092 Added 101.44%	91,529 $1.68 Million
Q2 2023 Aug 15, 2023	BUY	$16.96 - $27.82 $173,619 - $284,793	10,237 Added 29.08%	45,437 $1.18 Million
Q3 2022 Nov 15, 2022	SELL	$11.58 - $24.73 $1.87 Million - $3.99 Million	-161,202 Reduced 82.08%	35,200 $632,000

Q2 2022 Aug 15, 2022	BUY	$8.52 - $25.26 $798,204 - $2.37 Million	93,686 Added 91.21%	196,402 $2.23 Million
Q1 2022 May 13, 2022	SELL	$19.89 - $43.18 $165,345 - $358,955	-8,313 Reduced 7.49%	102,716 $2.29 Million
Q4 2021 Feb 14, 2022	BUY	$26.75 - $46.02 $305,672 - $525,870	11,427 Added 11.47%	111,029 $4.85 Million
Q3 2021 Nov 10, 2021	BUY	$25.18 - $37.81 $1.9 Million - $2.86 Million	75,626 Added 315.42%	99,602 $3.32 Million
Q2 2021 Jul 30, 2021	BUY	$14.69 - $27.52 $352,207 - $659,819	23,976 New	23,976 $660,000

Others Institutions Holding INBX

# of Institutions

132

Shares Held

35.5M

Call Options Held

64.8K

Put Options Held

91.3K

View Full List

About Inhibrx, Inc.

Ticker INBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,057,700
Market Cap $553M
Description
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...

More about INBX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.

Account

Alliancebernstein L.P. Inhibrx, Inc. Transaction History